2024
A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of Prevotella histicola, in adults with mild-to-moderate plaque psoriasis
Ehst B, Strober B, Blauvelt A, Maslin D, Macaro D, Carpenter N, Bodmer M, McHale D. A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of Prevotella histicola, in adults with mild-to-moderate plaque psoriasis. Frontiers In Medicine 2024, 11: 1292406. PMID: 38813388, PMCID: PMC11133679, DOI: 10.3389/fmed.2024.1292406.Peer-Reviewed Original ResearchPASI-50Double-blindMild to moderate plaque psoriasisMild to moderate psoriasisOff-treatment responseWeeks of follow-upChronic inflammatory skin diseaseParallel-group studySystemic anti-inflammatory responsePhase 2 trialInflammatory skin diseaseAnti-inflammatory responsePlaque psoriasisPlacebo-controlledPsoriasis AreaEfficacy outcomesImmunomodulatory approachesSafety profileAdverse eventsEvaluate safetyFollow-upTreatment periodTherapeutic benefitPsoriasisSkin diseases503 - Visualizing 3-year treatment outcome trajectories of dupilumab in adults with moderate-to-severe atopic dermatitis in real world practice
Wang Z, Martins B, Ardeleanu M, Yang M, Bégo-Le-Bagousse G, Sierka D, Strober B. 503 - Visualizing 3-year treatment outcome trajectories of dupilumab in adults with moderate-to-severe atopic dermatitis in real world practice. British Journal Of Dermatology 2024, 190: ii9-ii9. DOI: 10.1093/bjd/ljad498.011.Peer-Reviewed Original ResearchHealth statusIndividual patient levelTreatment satisfactionAtopic Dermatitis Control ToolPatient levelQuality of life of childrenObservational study of adultsAtopic dermatitisLongitudinal cohort studyPatient-reported outcomesPatient support programStudy of adultsQuality of lifeDupilumab treatmentMonth 1Lives of childrenBaseline surveyChronic inflammatory skin diseasePatients maintained responseSupport programsModerate-to-severe ADCohort studyLong-term treatmentInflammatory skin diseaseOutcome trajectoriesEfficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)
Strober B, Bachelez H, Crowley J, Elewski B, Gooderham M, Menter A, Strohal R, Chen M, Wu T, Zhan T, Photowala H, Armstrong A. Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). Journal Of The European Academy Of Dermatology And Venereology 2024, 38: 864-872. PMID: 38179809, DOI: 10.1111/jdv.19748.Peer-Reviewed Original ResearchSevere plaque psoriasisLong-term efficacyPlaque psoriasisDisease manifestationsWeek 256Palmoplantar psoriasisSubgroup analysisDurable long-term efficacyOpen-label extension studyBaseline patient characteristicsProportion of patientsBody mass indexInflammatory skin diseaseMultiple clinical manifestationsPASI 90/100Psoriatic manifestationsRisankizumab treatmentBaseline characteristicsPatient characteristicsPsoriasis AreaSkin psoriasisMass indexClinical manifestationsArthritis statusPatient subgroups
2023
Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry
Strober B, Ferris L, Callis Duffin K, Janak J, Sima A, Eckmann T, Patel M, Photowala H, Garg V, Armstrong A. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2023, 90: 82-90. PMID: 37739267, DOI: 10.1016/j.jaad.2023.08.097.Peer-Reviewed Original ResearchDermatology Life Quality Index scoresLife Quality Index scoresPsoriasis RegistryQuality Index scoresSevere psoriasisPsoriasis symptomsClear skinIndex scoreReal-world treatment effectivenessPrior biologic treatmentSevere plaque psoriasisInflammatory skin diseasePatient-reported outcomesEntire study populationReal-world effectivenessSignificant reductionPlaque psoriasisEligible adultsPatient adherenceBiologic treatmentActivity impairmentObservational studyStudy populationRisankizumabPsoriasisPharmacology of orismilast, a potent and selective PDE4 inhibitor
Silverberg J, French L, Warren R, Strober B, Kjøller K, Sommer M, Andres P, Felding J, Weiss A, Tutkunkardas D, Skak‐Nielsen T, Guttman E. Pharmacology of orismilast, a potent and selective PDE4 inhibitor. Journal Of The European Academy Of Dermatology And Venereology 2023, 37: 721-729. PMID: 36527389, DOI: 10.1111/jdv.18818.Peer-Reviewed Original ResearchConceptsChronic inflammatory skin diseasePeripheral blood mononuclear cellsEar thicknessPhosphodiesterase 4Clinical developmentBroad-spectrum anti-inflammatory activityPDE4 inhibitorsEx vivoHuman peripheral blood mononuclear cellsTumor necrosis factor αSecond-generation PDE4 inhibitorsEar skin inflammationWhole bloodMarkers of inflammationAnti-inflammatory effectsInflammatory skin diseasePro-inflammatory cytokinesBlood mononuclear cellsNovel treatment optionsNecrosis factor αPre-clinical modelsAnti-inflammatory activitySelective PDE4 inhibitorLong-term managementPBMC production
2022
Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance
Reich K, Gordon K, Strober B, Langley R, Miller M, Yang Y, Shen Y, You Y, Zhu Y, Foley P, Blauvelt A. Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance. Journal Of The European Academy Of Dermatology And Venereology 2022, 36: 2393-2400. PMID: 35920762, DOI: 10.1111/jdv.18474.Peer-Reviewed Original ResearchConceptsGlobal assessment scoreInvestigator's Global Assessment scoreSevere psoriasisGuselkumab treatmentChronic immune-mediated inflammatory skin diseaseBody weightImmune-mediated inflammatory skin diseaseAssessment scoresStepwise logistic regression analysisBaseline Psoriasis AreaComplete skin clearanceEarly clinical responseLess obese patientsVOYAGE 2 studiesBaseline body weightSubset of patientsInflammatory skin diseaseLogistic regression analysisHuman monoclonal antibodyPASI 100PASI 75Skin clearanceBaseline characteristicsBaseline demographicsClinical responseA Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17
Armstrong A, Blauvelt A, Mrowietz U, Strober B, Gisondi P, Merola J, Langley R, Ståhle M, Lebwohl M, Netea M, Nunez Gomez N, Warren R. A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17. Dermatology And Therapy 2022, 12: 787-800. PMID: 35167107, PMCID: PMC8941045, DOI: 10.1007/s13555-022-00687-0.Peer-Reviewed Original ResearchIL-23/ILOral candidiasisImmune-mediated inflammatory skin diseaseCo-existing diabetesGood oral hygieneInflammatory skin diseaseDysregulation of cytokinesStandard antifungal therapyAntifungal host defensePlaque psoriasisBiologic therapyInterleukin-17Oral hygieneAntifungal therapyPsoriasisPatientsSkin diseasesCandidiasisHost defenseFungal infectionsCytokinesTherapyTreatmentILPractical guide
2005
Off-Label Dermatologic Uses of Anti-TNF-a Therapies
Alexis A, Strober B. Off-Label Dermatologic Uses of Anti-TNF-a Therapies. Journal Of Cutaneous Medicine And Surgery 2005, 9: 296-302. PMID: 16699906, DOI: 10.1007/s10227-005-0110-7.Peer-Reviewed Original ResearchMeSH KeywordsAdalimumabAdolescentAdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedArthritis, PsoriaticChildChild, PreschoolChi-Square DistributionEtanerceptFemaleHumansImmunoglobulin GInfantInfliximabMalePsoriasisRandomized Controlled Trials as TopicReceptors, Tumor Necrosis FactorSkin DiseasesTime FactorsTumor Necrosis Factor-alphaConceptsDermatologic usesTNF inhibitorsDermatologic diseasesSneddon-Wilkinson diseaseInflammatory skin diseaseSmall case seriesNecrobiosis lipoidica diabeticorumPityriasis rubra pilarisMethodsA MEDLINE searchNumerous inflammatory skin diseasesIndividual case reportsApthous stomatitisBehçet's diseaseEosinophilic fasciitisSAPHO syndromeCase seriesCicatricial pemphigoidCrohn's diseaseMulticentric reticulohistiocytosisImmunomodulatory roleProinflammatory cytokinesCase reportLabel useMEDLINE searchSkin diseasesOff-Label Dermatologic Uses of Anti-TNF-a Therapies
Alexis A, Strober B. Off-Label Dermatologic Uses of Anti-TNF-a Therapies. Journal Of Cutaneous Medicine And Surgery 2005, 9: 296-302. DOI: 10.1177/120347540500900605.Peer-Reviewed Original ResearchDermatologic usesTNF inhibitorsDermatologic diseasesSneddon-Wilkinson diseaseInflammatory skin diseaseSmall case seriesNecrobiosis lipoidica diabeticorumPityriasis rubra pilarisNumerous inflammatory skin diseasesIndividual case reportsApthous stomatitisBehçet's diseaseEosinophilic fasciitisSAPHO syndromeAnti-TNFCase seriesCicatricial pemphigoidCrohn's diseaseMulticentric reticulohistiocytosisImmunomodulatory roleProinflammatory cytokinesCase reportLabel useTumor necrosisMEDLINE search